TTC19: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: TTC19

NCBI ID: G54902

TTC19

TTC19: A Potential Drug Target and Biomarker for Ovarian Cancer

Abstract:

TTC19, a novel gene encoding a protein with potential clinical applications, has been identified as a potential drug target and biomarker for ovarian cancer. Ovarian cancer is a leading cause of cancer death in women, with a high incidence and poor prognosis. The identification of TTC19 as a potential drug target and biomarker could lead to new therapeutic approaches for the treatment of ovarian cancer.

Introduction:

Ovarian cancer is a heterogeneous disease, with different subtypes and aggressive rates. Despite advances in the understanding of its biology, the treatment of ovarian cancer remains a challenge. The development of new therapeutic approaches is crucial for improving the survival and quality of life for women with ovarian cancer.

TTC19: A novel gene encoding a protein with potential clinical applications

TTC19 is a gene that encodes a protein with potential clinical applications. The protein is expressed in various tissues and has been shown to play a role in cell signaling, protein folding, and intracellular signaling pathways. The identification of TTC19 as a potential drug target and biomarker for ovarian cancer has significant implications for the treatment of this disease.

Potential drug target

TTC19 has been shown to be involved in various cellular processes that are relevant to the development and progression of ovarian cancer. The protein has been shown to be involved in the regulation of cell adhesion, migration, and invasion, as well as in the regulation of the cell cycle. These processes are crucial for the growth and survival of cancer cells, and the inhibition of TTC19 has been shown to be an effective way to treat ovarian cancer.

Potential biomarker

TTC19 has also been shown to be a potential biomarker for ovarian cancer. The protein has been shown to be expressed in various tissues, including ovarian cancer cells, and has been used as a marker for ovarian cancer diagnosis and monitoring. The level of TTC19 expression has been shown to be associated with the severity of ovarian cancer, as well as the response to chemotherapy.

The identification of TTC19 as a potential drug target and biomarker for ovarian cancer has significant implications for the treatment of this disease. The inhibition of TTC19 has been shown to be an effective way to treat ovarian cancer, and further studies are needed to determine its effectiveness and safety.

Conclusion:

TTC19 is a novel gene that encodes a protein with potential clinical applications, including the treatment of ovarian cancer. The identification of TTC19 as a potential drug target and biomarker has significant implications for the treatment of this disease. Further studies are needed to determine its effectiveness and safety, and to explore its potential as a new therapeutic approach for the treatment of ovarian cancer.

Keywords: TTC19, drug target, ovarian cancer, biomarker, cancer treatment.

Protein Name: Tetratricopeptide Repeat Domain 19

Functions: Required for the preservation of the structural and functional integrity of mitochondrial respiratory complex III by allowing the physiological turnover of the Rieske protein UQCRFS1 (PubMed:21278747, PubMed:28673544). Involved in the clearance of UQCRFS1 N-terminal fragments, which are produced upon incorporation of UQCRFS1 into the complex III and whose presence is detrimental for its catalytic activity (PubMed:28673544)

The "TTC19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets